A Potential Turning Point in Cancer Treatment: Targeting PHIP to Overcome SWI/SNF Inactivation
- New Vulnerability Identified: Researchers at St. Jude Children’s Research Hospital have pinpointed PHIP as a critical protein cancer cells rely on when the SWI/SNF complex is disabled – a common occurrence in roughly 25% of all cancers.
- Rhabdoid Tumors as a Model: The study leveraged the unique genetic simplicity of rhabdoid tumors to isolate the role of PHIP, offering a clearer path to therapeutic development than often found in more complex adult cancers.
- Drug Development Potential: While no drugs currently target PHIP, the research reveals its crucial function and identifies existing chemical inhibitors as potential starting points for new cancer therapies.
The fight against cancer is increasingly focused on understanding not just the genes *causing* the disease, but also the vulnerabilities that arise when key tumor suppressor systems are knocked out. This latest research, published in Nature Communications, represents a significant step forward on that front. For years, scientists have struggled to target cancers with mutations in the SWI/SNF chromatin-remodeling complex. The problem? These cancers often lose the very parts of the complex that would normally be good drug targets. This study shifts the focus – identifying a protein cancer cells become *dependent* on when SWI/SNF is broken.
The SWI/SNF complex is essential for controlling access to DNA, essentially dictating which genes are turned on or off. When it’s disrupted, cancer cells scramble to maintain proper gene regulation. Researchers, led by Dr. Charles Roberts at St. Jude, discovered that the protein PHIP plays a crucial role in this scramble. Using data from over 1,000 cancer cell lines – including a dedicated set of rhabdoid tumor cells – they found that PHIP becomes essential for survival when SWI/SNF is inactive.
Rhabdoid Tumors: A Crucial Window
The choice to focus on rhabdoid tumors, aggressive cancers primarily affecting young children, was strategic. These tumors are frequently caused by the loss of SMARCB1, a key component of the SWI/SNF complex. Crucially, rhabdoid tumors typically have few other genetic mutations, providing a relatively “clean” system to study the consequences of SWI/SNF disruption. As Dr. Roberts explains, this allows researchers to isolate the effects of SWI/SNF loss without the confounding influence of numerous other genetic changes often seen in adult cancers.
The research revealed a fascinating interplay between SWI/SNF and another complex, NuRD. SWI/SNF typically activates genes, while NuRD silences them. PHIP acts as a crucial mediator, suppressing NuRD’s silencing activity and allowing SWI/SNF to properly activate genes. When SWI/SNF is absent, PHIP becomes essential to keep NuRD in check, preventing inappropriate gene silencing.
The Forward Look: From Discovery to Therapies
The identification of PHIP as a critical dependency is a major breakthrough, but the work doesn’t stop here. The next crucial steps will center around translating this discovery into tangible therapies. While no drugs currently target PHIP, the researchers have identified chemical inhibitors that show promise. Expect to see increased investment in developing and refining these inhibitors, with a focus on specificity to minimize off-target effects. Furthermore, the team’s findings will likely spur broader research into the SWI/SNF-NuRD axis in other cancers where SWI/SNF is mutated.
The Pediatric Cancer Dependencies Accelerator, a collaborative effort involving St. Jude and the Broad Institute, will undoubtedly play a key role in accelerating this process. The availability of comprehensive cancer cell line data, coupled with the insights gained from rhabdoid tumor models, provides a powerful platform for identifying and validating new therapeutic targets. The overexpression of PHIP and its association with poor prognosis in several cancers suggests a broad potential impact beyond rhabdoid tumors, making this a particularly exciting area of oncology research. Clinical trials, while still several years away, are now a realistic prospect, offering a potential new lifeline for patients battling these challenging malignancies.
Discover more from Archyworldys
Subscribe to get the latest posts sent to your email.
